

87219\_Auto\_Edited.docx

**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 87219

**Manuscript Type:** CASE REPORT

## **Warthin-like papillary renal cell carcinoma: A case report**

Xiu-Feng Li, Zheng-Jiang Wang, Heng-Ming Zhang, Mai-Qing Yang

### **Abstract**

#### **BACKGROUND**

Warthin-like papillary renal cell carcinoma (WPRCC) has been described as a rare pathological subtype of papillary renal cell carcinoma in the 2022 World Health Organization Classification of the Urinary and Male Reproductive System. Herein we report a case of WPRCC in the left kidney.

#### **CASE SUMMARY**

Physical examination of a previously healthy 47-year-old woman revealed a lump in her left kidney, 4.5 cm × 3.5 cm × 3.5 cm in size. Based on the clinical information, imaging data, histomorphological features, and immunohistochemistry results, the pathological diagnosis was WPRCC in left kidney.

#### **CONCLUSION**

Resection of the mass in the left kidney was performed and her postoperative course was uneventful.

7

### **INTRODUCTION**

Renal cell carcinoma (RCC) is a highly heterogeneous group of tumors comprising about 24 subtypes recognized in the latest World Health Organization (WHO)

classification. It is characterized by papillary or tubulopapillary structures. Warthin-like papillary renal cell carcinoma (WPRCC) is described as a rare pathological subtype of PRCC in the 2022 WHO classification system<sup>[1]</sup>. Therefore, its clinicopathological features and prognosis need to be summarized and analyzed in additional cases.

## **CASE PRESENTATION**

### ***Chief complaints***

A woman (47 old) presented with abdominal distension for 3 d. Computed tomography (CT) revealed a high-density mass in the left kidney. However, the patient did not present with any relevant symptoms. She was admitted to our hospital for surgical treatment.

### ***History of present illness***

The patient had no additional illness.

### ***Past <sup>6</sup>history of illness***

The patient was previously in good health.

### ***Personal and family history***

Personal history, family histories, medication history, social history, and allergy history were negative.

### ***Physical examination***

Physical examination showed normalities.

### ***Laboratory examinations***

Laboratory examinations showed no abnormalities. Serum alkaline phosphatase level was 54 U/L (normal 34-150 U/L), serum glutamic-oxalacetic transaminase (SGOT) level

was 16 U/L (normal 0-35 U/L), glutamic-pyruvic transaminase (SGPT) was 18 U/L (normal range, 0-40 U/L), and SGOT/SGPT was 0.93.

### *Imaging examinations*

Chest CT was normal. Abdominal CT showed no liver, gallbladder, pancreas, spleen, and right kidney abnormalities. Contrast-enhanced CT showed a slightly high-density lesion in the left kidney, approximately 4.7 cm × 3.8 cm in size (Figure 1). There was no evidence of metastasis to other organs. The preoperative diagnosis was renal cancer.

### **FINAL DIAGNOSIS**

Primary Warthin-like papillary renal cell carcinoma.

### **TREATMENT**

A laparoscopic resection of the left renal mass was performed. After surgery, <sup>1</sup>the patient did not receive any postoperative radiotherapy or chemotherapy and recovered well. The resected renal specimen was 5 cm × 5 cm × 3 cm in size, adjacent to the renal capsule and 0.3 cm away from the broken end of the kidney, a mass with a volume of 4.5 cm × 3.5 cm × 3.5 cm was observed, and the section was sallow and medium in quality. The tumor mass was completely resected with no residual tumor at the resection margin. <sup>1</sup>The resected tissues were fixed with 10% neutral-buffered formalin, then embedded into tissue paraffin blocks, cut into 4 μm thick sections. The sections were stained with hematoxylin and eosin to observe the tissue morphology.

Appropriate tissue sections were selected for immunohistochemical staining with ready-to-use primary antibodies against broad-spectrum cytokeratin (CK), CK7, P504S, pair box gene-8 (PAX-8), Vimentin, transcription factor binding to IGHM enhancer 3 (TFE3), Succinate dehydrogenase (SDHB), fumarate hydratase (FH), CD10, RCC marker, CD15, CD117, carbonic anhydrase IX (CAIX), E-Cadherin, CK20, thyroid transcription factor-1 (TTF-1), <sup>3</sup>mutL homolog 1 (MLH1), mutS homolog 2 (MSH2), CD3, CD20, mutS homolog 6 (MSH6), postmeiotic segregation increased 2 (PMS2), Ki-67

(Maixin, Fuzhou, China). Immunohistochemistry was performed using EnVision method and simultaneously stained with colloidal iron.

For testing chromosomes 7 and 17, a kit was purchased from Kanglu Biotechnology Co., Ltd. (Wuhan, China). The testing steps were carried out according to the manufacturer's instructions on tissue 4  $\mu$ m thick. Fluorescence in situ hybridization signals were observed using a fluorescence microscope equipped with appropriate filters to visualize the intense yellow-green hybrid signals of the counterstained nuclei. Cases with average copy numbers of CEP7 and CEP17  $\geq 10\%$  were defined as CEP7 and CEP17 amplifications, respectively.

Microscopically, the boundary between the tumor and surrounding normal renal tissue was clear, the tumor was distributed in sheets, and lymphoid cell infiltration was observed in the tumor stroma (Figure 2A). The tumor cells were arranged in glandular or tubular forms, with more lymphocyte infiltrates in the interstitial area, lymphatic follicle formation, and no fibrous septa. The tumor cytoplasm was eosinophilic, the tumor nucleus was medium-sized, the nucleoli could be seen, and the middle and upper parts of the cell were located in the nucleus (Figure 2B). The tumor invaded the renal capsule, but there was no clear cancer thrombus in the vasculature or nerves. Immunohistochemically, the tumor cells were positive for CK, CK7, P504S, PAX-8, Vimentin, TFE3, SDHB, FH; partial expression of CD10, RCC marker, and CD15; negative expression of CD117, CAIX, E-cadherin, CK20, and TTF-1; and the tumor mesenchymal lymphocytes expressed CD3 (T lymphocytes) and CD20 (B lymphocytes). Mismatch repair proteins (MLH1, MSH2, MSH6, and PMS2) were not lost. The Ki-67 index of the tumor cells was approximately 2%. Colloidal iron staining results were negative (Figure 3). This patient showed a gain in chromosomes 7 and 17 (Figure 4).

### **OUTCOME AND FOLLOW-UP**

Follow-up 8 mo, there wasn't any evidence of recurrence or other metastatic diseases. The patient had three follow-up visits since the treatment of the primary tumor until now, and the results of three examinations, such as chest and abdominal CT, laboratory

examinations were normal. No tumor cells were found in postoperative urine exfoliative cytology examination.

## **DISCUSSION**

After <sup>5</sup>clear cell RCC, PRCC is the second most common type of RCC, accounting for approximately 13%-20% of epithelial renal tumors, most of which occur in adults<sup>[2]</sup>. Recently, several new tumor types with papillary features have emerged, including <sup>2</sup>papillary renal neoplasms with reversed polarity, biphasic hyalinizing psammomatous RCC, biphasic squamoid/alveolar RCC, thyroid-like follicular RCC, and RCC with different molecular changes<sup>[3,4]</sup>.

Carcinomas resembling benign Warthin tumors have been reported in the salivary and thyroid glands, but rarely in the kidneys<sup>[5,6]</sup>. Therefore, WPRCC is considered a rare variant of PRCC as cytoplasmic eosinophilic PRCC is very similar to eosinophilic PRCC, with the main difference being the presence of dense lymphoid interstroma in the former. Table 1<sup>[7]</sup> summarized the clinicopathological features of all patients. Of the patients with primary WPRCC included in our previous study, 3 were female and 9 were male. The patient age varied widely, ranging from 14–76 years (mean age: 57.7 years) (one not available). The diameters of the tumors ranged from 1.0–22 cm (mean diameter: 6.8 cm) (one not available)<sup>[7]</sup>.

Current available data suggest that specific tumor-infiltrating lymphocyte phenotypes may have prognostic and/or therapeutic value; meanwhile, the characteristics of RCC remain unclear<sup>[8,9]</sup>. Tumor-infiltrating and peritumorous <sup>4</sup>lymphocytes are common in cancers associated with Lynch syndrome (LS), an inherited cancer syndrome caused by mutations in the DNA mismatch repair (MMR) protein. To determine whether WPRCC is related to LS, the above study also observed the expression of four MMR proteins (MSH2, MSH6, PMS2, and MLH1), as there are dense lymphocytes in the interstitium of WPRCC. The results showed that only one case had MSH2 and MSH6 deletions, and continued MLH1 promoter methylation and BRAF V600E mutation analyses of the deletion cases revealed no abnormalities. This suggests

that there is no correlation between WPRCC and LS<sup>[7]</sup>. No loss in MMR protein expression was observed. Skenderi *et al*<sup>[7]</sup> performed molecular genetic analyses on 9 of 11 cases of WPRCC and found that 5 patients showed significant variation, ranging from single chromosome loss to complex genome rearrangement, while only one of these five patients showed an increase in chromosomes 7 and 17, which was basically the same as the cases we reported and considered characteristic of PRCC.

Some tumors with similar histological characteristics, such as renal eosinophilic adenoma, FH-deficient RCC, renal clear cell carcinoma, and chromophobe RCC, must be distinguished from WPRCC. Renal eosinophilic adenoma is a benign tumor with a common star-shaped scar, and the significant difference between CD117 and vimentin in the two types of tumors is helpful in differentiating them. FH-deficient RCC often shows a mixture of papillary, cribriform, tubular and cystic structures, and cancer cells often show characteristic perinucleolar halos. Immunohistochemical staining of FHs is helpful in differentiating them. In chromophobe RCC, the tumors are lamellar, and adenoid, with thick-walled blood vessels in the tumor stroma; CD117 and colloidal iron are positively expressed, and vimentin is negatively expressed in chromophobe RCC, which could be used to distinguish WPRCC<sup>[1]</sup>.

Complete surgical resection of renal WPRCCs is feasible. All 11 patients underwent surgery alone. Definitive histopathological prognostic factors of renal WPRCC have not been fully clarified due to its rarity. Of the 11 patients, 3 cases of WPRCC have metastatic potential, and additional cases should be studied. In our case, the patient underwent only surgery and survived without recurrence for 8 mo after surgery. Papillary tumors are more likely to be bilateral and multifocal, especially when accompanying trisomy 7 and/or trisomy 17, the patient of our case had three follow-up visits since the treatment of the primary tumor until now, and the results of three examinations, such as chest and abdominal CT, laboratory examinations were normal. Due to the short follow-up time, we need to follow up this case more closely in the future.

## **CONCLUSION**

In summary, WPRCC is a rare PRCC, and careful assessment of its histological features and immunohistochemistry enables an efficient diagnosis. An accurate diagnosis is crucial for treatment and prognostic assessment. Complete surgical resection is the treatment of choice.



# 8%

SIMILARITY INDEX

### PRIMARY SOURCES

- |          |   |                      |
|----------|---|----------------------|
| <b>1</b> | <a href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a><br><small>Internet</small>   | 53 words — <b>3%</b> |
| <hr/>    |   |                      |
| <b>2</b> | María José Méndez-Vidal, Martin Lázaro Quintela, Nuria Lainez-Milagro, Begoña Perez-Valderrama et al. "SEOM SOGUG clinical guideline for treatment of kidney cancer (2022)", Clinical and Translational Oncology, 2023<br><small>Crossref</small> | 17 words — <b>1%</b> |
| <hr/>    |   |                      |
| <b>3</b> | <a href="http://journal.hep.com.cn">journal.hep.com.cn</a><br><small>Internet</small>   | 17 words — <b>1%</b> |
| <hr/>    |   |                      |
| <b>4</b> | <a href="http://www.longdom.org">www.longdom.org</a><br><small>Internet</small>   | 15 words — <b>1%</b> |
| <hr/>    |   |                      |
| <b>5</b> | Genitourinary Pathology, 2015.<br><small>Crossref</small>   | 14 words — <b>1%</b> |
| <hr/>    |   |                      |
| <b>6</b> | Si-Cong Chen, Dong-Heng Ma, Jia-Jian Zhong. "Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report", World Journal of Clinical Cases, 2023<br><small>Crossref</small>                  | 14 words — <b>1%</b> |
| <hr/>    |   |                      |
| <b>7</b> | Faruk Skenderi, Monika Ulamec, Tomas Vanecek, Petr Martinek et al. "Warthin-like papillary renal cell carcinoma: Clinicopathologic, morphologic,  | 12 words — <b>1%</b> |

immunohistochemical and molecular genetic analysis of 11 cases", Annals of Diagnostic Pathology, 2017

Crossref

---

EXCLUDE QUOTES	ON	EXCLUDE SOURCES	OFF
EXCLUDE BIBLIOGRAPHY	ON	EXCLUDE MATCHES	< 12 WORDS